Exclusive Patent License Agreement Sample Contracts
RECITALSExclusive Patent License Agreement • May 13th, 2005 • Avanir Pharmaceuticals • Pharmaceutical preparations
EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • May 5th, 2020 • California
This Exclusive Patent License Agreement (the “Agreement” and/or “EPLA”) is made and entered into by and between Therapeutic Solutions International, Inc., a corporation organized under Nevada law (hereinafter the “Licensor”), having its principle office at 4093 Oceanside Blvd., Suite B, Oceanside CA, 92056, and Emvolio, Inc., a corporation organized under the laws of Delaware (hereinafter the “Licensee”), its principle office being located in Oceanside, California. Licensor and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” The Parties agree as follows:
EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • April 24th, 2025 • Colorado
This License Agreement (hereinafter “Agreement”), which shall be effective on the date it is executed by the last Party to sign (the “Effective Date”) below, is between Alliance for Sustainable Energy, LLC (hereinafter "Alliance"), Management and Operating Contractor for the National Renewable Energy Laboratory (hereinafter “NREL”) located at 15013 Denver West Parkway, Golden, Colorado 80401 and [COMPANY NAME], (hereinafter "Licensee"), a for-profit company organized and existing under the laws of the State of [NAME of STATE] and having a principal place of business at [COMPANY ADDRESS], hereinafter referred to individually as “Party” and jointly as “Parties”.
SECOND EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN BIOMIMETIC PHARMACEUTICALS, INC. AND ZYMOGENETICS, INC.Exclusive Patent License Agreement • May 10th, 2006 • Biomimetic Therapeutics, Inc. • Surgical & medical instruments & apparatus • Washington
CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “****” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND...Exclusive Patent License Agreement • July 23rd, 2014 • MetaStat, Inc. • Semiconductors & related devices • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the "EFFECTIVE DATE"), is between the Massachusetts Institute of Technology ("M.I.T."), a corporation organized and existing under the laws of the State of Massachusetts, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307, Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, a corporation organized and existing under the laws of the State of New York, having a place of business at 1300 Morris Park Avenue, Bronx, New York 10461 (“EINSTEIN”), Montefiore Medical Center, a corporation organized and existing under the laws of the State of New York, having an office and place of business at 111 East 210th Street, Bronx, New York 10467 (“MONTEFIORE”) (M.I.T., EINSTEIN, and MONTEFIORE shall be referred to individually and collectively as “THE PARTIES”), and MetaStat BioMedical, Inc., a corporation organized and existing under the laws o
University of Minnesota EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • August 11th, 2017 • GT Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis, Minnesota 55455 (the “University”), and the Licensee identified below. The University and the Licensee agree that:
EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN THE UNIVERSITY OF TEXAS SYSTEM AND MIRAGEN THERAPEUTICS, INC.Exclusive Patent License Agreement • January 4th, 2017 • Signal Genetics, Inc. • Services-medical laboratories • Texas
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (“AGREEMENT”) is between the Board of Regents (“BOARD”) of The University of Texas System (“SYSTEM”), an agency of the State of Texas, on behalf of The University of Texas Southwestern Medical Center at Dallas, whose address is 5323 Harry Hines Boulevard, Dallas, Texas 75390-9094 (“UT SOUTHWESTERN”), a component institution of SYSTEM, and Miragen Therapeutics, Inc. (“LICENSEE”), a Delaware corporation having a principal place of business located at 1900 Ninth Street, Suite 200, Boulder, Colorado 80302.
EX-10.12 12 d269230dex1012.htm EX-10.12 CONFIDENTIAL TREATMENT REQUESTED EXCLUSIVE PATENT LICENSE AGREEMENT by and between MERCK, SHARP & DOHME CORPORATION and TARGENICS, Inc. CONFIDENTIAL TREATMENT REQUESTED EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • May 5th, 2020 • New York
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”), dated as of December 12, 2012 (the “Effective Date”), is by and between Merck, Sharp & Dohme Corporation, a corporation organized and existing under the laws of New Jersey (hereinafter referred to as “Merck”), and Targenics, Inc., a corporation organized and existing under the laws of Delaware (hereinafter referred to as “Licensee”). Merck and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “****” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND...Exclusive Patent License Agreement • July 23rd, 2014 • MetaStat, Inc. • Semiconductors & related devices • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the “EFFECTIVE DATE”), is between the Massachusetts Institute of Technology (“M.I.T.”), a corporation organized and existing under the laws of the State of Massachusetts, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307, Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, a corporation organized and existing under the laws of the State of New York, having a place of business at 1300 Morris Park Avenue, Bronx, New York 10461 (“EINSTEIN”), Montefiore Medical Center, a corporation organized and existing under the laws of the State of New York, having an office and place of business at 111 East 210th Street, Bronx, New York 10467 (“MONTEFIORE”) (M.I.T., EINSTEIN, and MONTEFIORE shall be referred to individually and collectively as “THE PARTIES”), and MetaStat BioMedical, Inc., a corporation organized and existing under the laws o
EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • September 10th, 2020 • New York
This agreement (hereinafter "Agreement"), effective as of this day of , 20 (hereinafter the “Effective Date”), is by and between the University of Rochester, an educational institution chartered by the State of New York and having its principal place of business at 601 Elmwood Avenue, Box URV, Rochester, New York 14642 (“University”) and
EX-10.13 14 a2236053zex-10_13.htm EX-10.13 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH and RUBIUS THERAPEUTICS, INC. EXCLUSIVE...Exclusive Patent License Agreement • May 5th, 2020 • Massachusetts
This Agreement, effective as of January 28, 2016, (the “EFFECTIVE DATE”), is by and between the Whitehead Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, with a principal office at Nine Cambridge Center, Cambridge, MA 02142, and Rubius Therapeutics, Inc. (“COMPANY”), formerly known as VL26, Inc., a Delaware corporation, with a principal place of business at 620 Memorial Drive, Suite 100 West, Cambridge, MA 02139.
THE GENERAL HOSPITAL CORPORATION EXCLUSIVE PATENT LICENSE AGREEMENT MGH Agreement No: 221771 MGII Case No: 21125Exclusive Patent License Agreement • April 24th, 2017 • Biohaven Pharmaceutical Holding Co Ltd. • Pharmaceutical preparations • Massachusetts
This License Agreement (“Agreement”) is made as of the 13 day of September, 2014 (“Effective Date”), by and between BioHaven Pharmaceutical Holding Company, a British Virgin Island corporation, having a principal place of business at Suite 304 / 234 Church Street / New Haven CT 06510 (“Company”) and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties”.
MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND BIND BIOSCIENCES, INC. EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • September 5th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the “EFFECTIVE DATE”), is between the Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and BIND Biosciences, Inc. (“COMPANY”), a Delaware corporation, with a principal place of business at 101 Binney Street, Cambridge, MA 02142.
EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • February 14th, 2012 • Atossa Genetics Inc • Surgical & medical instruments & apparatus • Washington
This Exclusive Patent License Agreement is made as of July 27, 2009 (“Effective Date”) between Ensisheim Partners, LLC, a Washington limited liability company (“Licensor”), and Atossa Genetics, Inc., a Delaware corporation (“Atossa”). The parties agree as follows:
VERSITECH LIMITED and ACTICULE LIFE SCIENCES LIMITED EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • April 15th, 2019 • Aptorum Group LTD • Pharmaceutical preparations • Hong Kong
THE GENERAL HOSPITAL CORPORATION EXCLUSIVE PATENT LICENSE AGREEMENT MGH Agreement No: [***] MGH Case No: MGH [***]Exclusive Patent License Agreement • August 30th, 2021 • HealthCor Catalio Acquisition Corp. • X-ray apparatus & tubes & related irradiation apparatus
This License Agreement (“Agreement”) is made as of the 29th day of May, 2014 (“Effective Date”), by and between Hyperfine Research, Inc., a corporation, having a principal place of business at 530 Old Whitfield Street, Guilford, CT 06437 (“Company”) and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties”.
EX-10.6 3 d370817dex106.htm EX-10.6 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE...Exclusive Patent License Agreement • May 5th, 2020 • Minnesota
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis, Minnesota 55455 (the “University”), and the Licensee identified below. The University and the Licensee agree that:
EXCLUSIVE PATENT LICENSE AGREEMENT by and between PURETECH VENTURES LLC and KARUNA PHARMACEUTICALS, INC.Exclusive Patent License Agreement • October 27th, 2020 • PureTech Health PLC • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the “Effective Date”), is between PureTech Ventures LLC, a Delaware limited liability company (“PureTech”), and Karuna Pharmaceuticals, Inc., a Delaware corporation (the “Company”). PureTech and the Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
EX-10.1 10 b68098btexv10w1.htm EX-10.1 EXCLUSIVE PATENT LICENSE - MITExclusive Patent License Agreement • May 5th, 2020 • Massachusetts
Ver. EQ.5/8/00 MASSACHUSETTS INSTITUTE OF TECHNOLOGY EXCLUSIVE PATENT LICENSE AGREEMENT This Agreement, effective as of the date set forth above the signatures of the parties below (the “EFFECTIVE DATE”), is between the Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and BioTrove, Inc., a corporation having its principal office at 620 Memorial Drive, Cambridge, MA 02139 (“COMPANY”). R E C I T A L S WHEREAS, M.I.T. is the owner of certain PATENT RIGHTS (as later defined herein) relating to M.I.T. Case No. 7967, “Method And Apparatus For Performing Microassays” by Ian Hunter and M.I.T. Case No. 9118, “Molecular Screening In An Array Of Through-holes”, by Colin J. Brenan And Tanya S. Kanigan and has the right to grant licenses under said PATENT RIGHTS; WHEREAS, Ian Hunter is an inventor of the PATENT RIGHTS and a current employee of M.I.T., and has or will shortly acquire equity in
EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN BIOMIMETIC PHARMACEUTICALS, INC. AND ZYMOGENETICS, INC.Exclusive Patent License Agreement • May 10th, 2006 • Biomimetic Therapeutics, Inc. • Surgical & medical instruments & apparatus • Washington
EX-10.6 11 a2236234zex-10_6.htm EX-10.6 Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential...Exclusive Patent License Agreement • May 5th, 2020 • Massachusetts
This License Agreement (“Agreement”) is made as of the tenth day of November, 2010 (“Effective Date”), by and between Aridis Pharmaceuticals, LLC, a California corporation, having an office at 5941 Optical Court, San Jose, CA 95138 (“Company”) and The Brigham and Women’s Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties”.
PUBLIC HEALTH SERVICE FIRST AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENT - L-249-2001/0 AMENDMENT L-249-2001/1Exclusive Patent License Agreement • May 10th, 2013 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations
This Amendment, L-249-2001/1, (“First Amendment”) of the Exclusive Patent License L-249-2001/0 (“Agreement”) is made between the National Institutes of Health (“NTH”), the Centers for Disease Control and Prevention (“CDC”), or the Food and Drug Administration (“FDA”), hereinafter singly or collectively referred to as (“PHS”), agencies of the United States Public Health Service within the Department of Health and Human Services (“DHHS”) through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A. and Can-Fite BioPharma, Ltd. having offices at the address indicated on the Signature Page, hereinafter referred to as “Licensee”.
MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND ENUMERAL BIOMEDICAL CORP EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • October 31st, 2014 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the "EFFECTIVE DATE"), is between the Massachusetts Institute of Technology ("M.I.T."), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and Enumeral Biomedical Corp., Inc. ("COMPANY"), a Delaware corporation, with a principal place of business at 1450 Broadway, 24th Floor, New York, NY 10018.
EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • November 1st, 2019 • BiomX Inc. • Blank checks • California
This License Agreement (“Agreement”) is made as of the 15th of December, 2017 (“Effective Date”), by and among BiomX Ltd., a Israeli corporation, having its principal place of business at 2 Ilan Ramon St. Ness Tziona, Israel (the “Company”), Keio University, a university duly organized and existing under the laws of Japan, having its principal address at 2-15-45 Mita, Minato-ku, Tokyo 108-8345, Japan (the “University”), and JSR Corporation, a company duly organized and existing under the laws of Japan, having its principal place of business at 1-9-2, Higashi-Shimbashi, Minato-ku, Tokyo, 105-8640, Japan (“JSR”), each referred to herein individually as a “Party” and collectively as the “Parties.”
SIXTH AMENDMENTExclusive Patent License Agreement • September 17th, 2014 • Medifocus Inc. • Surgical & medical instruments & apparatus
This Sixth Amendment, effective as of the date set forth above the signatures of the parties below, amends the Exclusive Patent License Agreement dated October 24, 1997 (“AGREEMENT”) between the Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts corporation having its principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts, 02139, USA and Cheung Laboratories, Inc.
Exclusive Patent License AgreementExclusive Patent License Agreement • August 19th, 2024 • SciSparc Ltd. • Pharmaceutical preparations
This Exclusive Patent License Agreement (the “Agreement”), effective as of the date set forth above the signatures of the parties below (the “Effective Date”), is between SciSparc Ltd., an Israeli company, with a principal office at 20 Raul Walenberg St., Tel Aviv, Israel (“Licensor”) and Polyrizon Ltd., an Israeli corporation, with a principal place of business at 5 Hatidhar St., R’annana, Israel (“Licensee”).
exclusive patent LICENSE AGREEMENT (With Comments)Exclusive Patent License Agreement • October 8th, 2020
The framework for the M3 agreement is one in which an R&D institution (university, polytechnic, R&D centre, among others, acting as legal entities) grants a exclusive license to exploit a patent right or a patent pending application to a individual or legal entity of a commercial nature.
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Exclusive Patent License Agreement • July 16th, 2021 • Candel Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (“Agreement”) is made as of the 15th day of September, 2020 (“Effective Date”), by and between Advantagene, Inc., a Delaware corporation, having a principal place of business at 440 Lexington Avenue, Auburndale, MA 02466 (“Company”) and The Brigham and Women’s Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. MASSACHUSETTS INSTITUTE OF TECHNOLOGY and A123 Systems, Inc. EXCLUSIVE PATENT LICENSE AGREEMENT Offer to continue negotiations...Exclusive Patent License Agreement • October 31st, 2008 • A123 Systems, Inc. • Miscellaneous electrical machinery, equipment & supplies • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the "EFFECTIVE DATE"), is between the Massachusetts Institute of Technology ("M.I.T."), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and A123 Systems, Inc. ("COMPANY"), a Massachusetts corporation, with a principal place of business at 1 Memorial Drive, 12th Floor, Cambridge, MA 02142.
Second Amendment to Exclusive Patent License Agreement A217008.05Exclusive Patent License Agreement • June 5th, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances
This Second Amendment (“Second Amendment”) to the Exclusive Patent License Agreement MGH # A217008, (the “Agreement”), dated July 23, 2013 is made as of June 23, 2017 (“Second Amendment Effective Date) by and between The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”) and ArcherDx, Inc., a Delaware Corporation, having a principal place of business at 2477 55th St. # 202 Boulder, Colorado 80301 (“Company”).
NORTHEASTERN UNIVERSITY EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • October 24th, 2019 • Massachusetts
, 20 (“Effective Date”) by and between Northeastern University (“NU” or “Licensor”), a Massachusetts not-for-profit institution of higher education having a principal place of business at 360 Huntington Avenue, Boston, MA 02115 and [INSERT COMPANY NAME] (“Company” or “Licensee”), a [BUSINESS ENTITY TYPE] having a principal place of business at [ADDRESS] (each individually referred to as a “Party” and collectively as the “Parties”).
EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN THE UNIVERSITY OF TEXAS SYSTEM AND RECITALS PAGE 1 SIGNATURES PAGE 11 EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN THE UNIVERSITY OF TEXAS SYSTEM ANDExclusive Patent License Agreement • May 5th, 2020 • Texas
THIS Agreement (AGREEMENT) is between the Board of Regents (BOARD) of The University of Texas System (SYSTEM), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas Southwestern Medical Center at Dallas (UT SOUTHWESTERN), a component institution of SYSTEM, and ________________ (LICENSEE), a _____________ corporation having a principal place of business located at _______________.
CONFIDENTIAL TREATMENT REQUESTED UNIVERSITY OF MINNESOTA EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • September 15th, 2015 • REGENXBIO Inc. • Biological products, (no disgnostic substances)
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “EPLA”) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis, Minnesota 55455 (the “University”), and the Licensee identified below. The University and the Licensee agree that:
EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • December 2nd, 2017
THE HYPERLINKED ANNOTATIONS IN THIS DOCUMENT ARE INTENDED TO HELP THE READER UNDERSTAND THE BASIS IN LAW OR UNIVERSITY POLICY FOR TERMS IN THE UNIVERSITY’S STANDARD EXCLUSIVE PATENT LICENSE AGREEMENT. THESE ANNOTATIONS ARE NOT INTENDED TO ALTER OR MODIFY THIS AGREEMENT. IF THERE IS ANY DISPUTE AS TO THE INTENT OR MEANING OF THE ANNOTATIONS VERSUS THE ACTUAL AGREEMENT, ONLY THE TEXT OF THE AGREEMENT IS INTENDED TO BE INTERPRETED
FIFTH AMENDMENTExclusive Patent License Agreement • September 17th, 2014 • Medifocus Inc. • Surgical & medical instruments & apparatus
This Fifth Amendment, effective as ofthe date set forth above the signatures ofthe parties below, amends the Exclusive Patent License Agreement dated October 24, 1997 (“AGREEMENT”) between the Massachusetts Institute of Technology (“M.l.T.”), a Massachusetts corporation having its principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts, 02139, USA and Cheung Laboratories, Inc.